title: High-dose cyclophosphamide without stem-cell rescue for refractory CIDP.
abstract: Four patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who were refractory to conventional treatment were treated with high-dose cyclophosphamide (200 mg/kg over 4 days). All improved in functional status and muscle strength. Nerve conduction studies improved in three of four. Other immunomodulatory medications have been discontinued. High-dose cyclophosphamide can be given safely to patients with CIDP and patients with disease persistence after standard therapy may have a response that lasts for over 3 years and results in long-term disease remission.
authors.affiliation: Department of Neurology, MCP-Hahnemann University, Philadelphia, PA, USA. THB2006@med.cornell.edu
authors.forename: T H
authors.initials: TH
authors.lastname: Brannagan
authors.forename: A
authors.initials: A
authors.lastname: Pradhan
authors.forename: T
authors.initials: T
authors.lastname: Heiman-Patterson
authors.forename: A C
authors.initials: AC
authors.lastname: Winkelman
authors.forename: M J
authors.initials: MJ
authors.lastname: Styler
authors.forename: D L
authors.initials: DL
authors.lastname: Topolsky
authors.forename: P A
authors.initials: PA
authors.lastname: Crilley
authors.forename: R J
authors.initials: RJ
authors.lastname: Schwartzman
authors.forename: I
authors.initials: I
authors.lastname: Brodsky
authors.forename: D E
authors.initials: DE
authors.lastname: Gladstone
mesh_terms: D000328:Adult; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide